iShares US Pharmaceuticals ETF
139 hedge funds and large institutions have $326M invested in iShares US Pharmaceuticals ETF in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 38 reducing their positions, and 25 closing their positions.
19% more capital inflows, than outflows
Capital inflows: $29.3M | Capital outflows: $24.6M
3.28% more ownership
Funds ownership: 55.86% → 59.14% (+3.3%)
5% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 38
7% less funds holding
Funds holding: 150 → 139 (-11)
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$13M |
| 2 |
JP Morgan Chase
New York
|
+$6.4M |
| 3 |
Goldman Sachs
New York
|
+$2.19M |
| 4 |
Grimes & Company
Westborough,
Massachusetts
|
+$1.46M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$10.8M |
| 2 |
ClearBridge Investments
New York
|
-$1.9M |
| 3 |
Morgan Stanley
New York
|
-$1.88M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.34M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.25M |
IHE Hedge Fund Activity: Q2 2025 in Review
139 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2025, worth a combined $326M — down 5.5% from $345M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of IHE and 14 opened new positions — a net loss of 11 holders — while 38 trimmed existing stakes and 40 added.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $13M. The largest seller was Fisher Asset Management, cutting an estimated $10.8M.
- 139 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2025, down from 150 in Q1 2025.
- Funds reported $326M of iShares US Pharmaceuticals ETF stock for Q2 2025, down 5.5% quarter-over-quarter.
- 14 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2025 and 25 closed out, a net change of -11 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2025 was BNP Paribas Financial Markets, an estimated $13M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2025 was Fisher Asset Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q2 2025.